Asthma Clinical Trial
Official title:
A Single Dose, Crossover Study in Healthy Female Subjects to Assess the Regional Absorption and Bioavailability of 100 mg GSK2190915A
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that
attenuates the production of leukotrienes through the blockage of the first step in the
leukotriene pathway, 5-lipoxygenase (5-LO) activation. GSK2190915 inhibits the production of
leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs).
This is an open label, 4-way, 4-treatment period, non-randomised, crossover study with an
interim analysis. The GSK2190915 formulations used in this study will be: a 100mg and 200mg
milled tablet, a 100mg enteric-coated tablet, and a [14C] radiolabelled GSK2190915
intravenous solution.
This study aims to determine the pharmacokinetics and absolute bioavailability of GSK2190915
to enable optimisation of suitable formulations to be used in clinical development Fourteen
subjects will be dosed to ensure data in 10 at the end of the clinical study. Seven of the
subjects will receive an IV microtracer in addition to the other treatments.
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that
attenuates the production of leukotrienes through the blockage of the first step in the
leukotriene pathway, 5-lipoxygenase (5-LO) activation. Leukotrienes are potent inflammatory
molecules produced mainly by mast cells, eosinophils, monocytes/macrophage and neutrophils in
response to allergic or inflammatory stimuli. GSK2190915 inhibits the production of
leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs).
This is an open label, 4-way, 4 treatment period, non-randomised, single-dose crossover study
with an interim analysis following the third treatment period. The GSK2190915 formulations
used are: milled 100mg and 200mg tablets, a 100mg enteric-coated tablet, and a [14C]
radiolabelled GSK2190915 intravenous solution.
There will be 4 periods. Period 1 includes two cohorts (of 7 subjects each), both of which
will be administered the 100mg GSK2190915 milled tablet orally; however, the second cohort
will in addition be dosed with an intravenous radiolabelled infusion of the drug. In the
second period, a 100mg dose of milled GSK2190915 tablet (a ground half of a 200mg tablet) is
administered directly to the proximal small bowel using an Enterion capsule. The same dose is
repeated in the third period, but is administered directly to the distal small bowel. An
interim analysis will then follow. The decision to proceed will be made following a review of
the pharmacokinetic data from the first three treatments. In the fourth and final period, the
treatment will be a 100mg enteric-coated tablet of GSK2190915 administered orally. There will
be a minimum washout of 7 days in between each period.
This study aims to determine the pharmacokinetics and absolute bioavailability of GSK2190915
to enable optimisation of suitable formulations to be used in clinical development. Periods 1
to 3 will characterise the absolute bioavailability of GSK2190915 using IV tracer and oral
formulation, in addition to defining the regional absorption characteristics of the drug when
released in the proximal and distal parts of the gastro-intestinal tract. The fourth period
will investigate the oral bioavailability of an enteric coated formulation of GSK2190915.
Fourteen subjects will be dosed to ensure data in 10 at the end of the clinical study. Seven
of the subjects (in cohort 2, Period 1) will receive an IV microtracer in addition to the
other treatments.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|